Overview
American Genomics is a precision-health and molecular diagnostics company using genomics, next-generation sequencing (NGS) and pharmacogenomics (PGx) to advance personalized and preventive care.
Both of its tests start from one simple at-home cheek swab. The PGx test looks at genetic differences that may affect how a person processes certain medications. The NGS test looks for inherited genetic changes linked to certain health conditions, including carrier information for family planning. Findings are reviewed by clinicians before release and delivered in plain-language reports patients can share with their providers.
The company brings together AI, genomic data, laboratory technology and clinical workflows to make complex genetic information actionable for healthcare professionals — part of a broader shift from reactive care toward predictive, preventive and personalized medicine.
Highlights
- PGx testing for medication response
- NGS testing for inherited health risk and carrier status
- At-home cheek swab — no needles or clinic visit
- Clinician-reviewed, plain-language reports
- Secure patient account with kit and lab tracking
- Medicare, private insurance and self-pay options
Leadership
American Genomics is led by Mohamed Shahram Marleen, Co-Founder & CEO, who also serves as Managing Partner of M3 Ventures.
